Boston Scientific To Study Complex Drug-Eluting Stent Use; Taxus Complaints Surface
This article was originally published in The Pink Sheet Daily
Executive Summary
The company is projecting worldwide Taxus revenue of $1.7 bil-$2.2 bil. for 2004, building on early 70% share claimed in the U.S. drug-eluting stent market. The paclitaxel-eluting stent's delivery platform has been subject to roughly 40 complaints since its launch in early March.
You may also be interested in...
CMS’ Plan To Fund Clinical Studies Seeks To Improve Data For Coverage Decisions
The Centers for Medicare & Medicaid Services’ move to cover carotid stent post-approval studies is in-line with recent Medicare trend to effectively promote data collection for national coverage determinations.
Gambro Settles Medicare Billing Suit, Signs Corporate Integrity Agreement
The company will pay up to $355 mil. to settle a Medicare billing fraud civil suit initiated by the Department of Justice. Gambro is absolved of claims against a dialysis supply subsidiary in exchange for a guilty plea to a single felony charge.
FDA Dental Panel Will Consider BioMimetic PMA For Periodontal Diseases July 13
Sankyo Pharmaceuticals unit Luitpold has exclusive rights to distribute GEM 21S dental osseous defect therapy. BioMimetic expects European approval in the first half of 2005.